Last update 12 Sep 2024

Pumecitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PG 011, PG-011, PG011
Mechanism
JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors)
Inactive Indication-
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-

Structure

Molecular FormulaC17H20N8O2S
InChIKeyOUXYFMCMGWQWQF-UHFFFAOYSA-N
CAS Registry2401057-12-1

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Dermatitis, AtopicPhase 3
CN
19 Mar 2023
Rhinitis, Allergic, SeasonalPhase 2
CN
12 Jan 2024
prurigo nodularisPhase 2
CN
17 Dec 2021
Rhinitis, AllergicPhase 1
CN
05 Sep 2023
Photosensitivity DisordersPhase 1
CN
-
RadiodermatitisPhase 1
CN
-
Epidermolysis Bullosa PruriginosaIND Approval
CN
07 Oct 2023
Nonsegmental vitiligoIND Approval
CN
29 Aug 2023
Epstein-Barr Virus InfectionsIND Application
CN
-
Epidermolysis BullosaPreclinical
US
30 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free